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Abstract
Introduction:New-type drugs are popular with adolescents and could lead to psychiatry disorders, but no medications have been
proven to be effective for these disorders of new-type drug dependence. We aimed to evaluate the efﬁcacy of tryptophan on sleeping
disorders and mental symptoms in detoxiﬁed individuals with new-type drug dependence.
Methods: This randomized, placebo-controlled trial included 80 detoxiﬁed individuals with new-type drug dependence, recruited
successively from a Compulsory Residential Drug Abstinence Institution inWuhan, China, from April 2012 to November 2012. Eligible
participants were randomly allocated to be treated with tryptophan (1000mg/d, n=40) or placebo (n=40) for 2 weeks. The sleeping
disorders andmental symptoms were assessed using Athens Insomnia Scale and SymptomCheck-List-90 at baseline and 2 weeks.
Results were analyzed according to the “intention-to-treat” approach.
Results: Forty-ﬁve participants completed the 2-week study, 24 in the tryptophan group and 21 in the placebo group. There were
no statistically signiﬁcant differences in baseline characteristics between groups and the treatment adherence was similar between
groups. The reduction in the Athens Insomnia Scale score in the tryptophan group was signiﬁcantly greater than that in the placebo
group (P=0.017). However, no signiﬁcant differences were found in Symptom Check-List-90 scores (either by individual dimension
or the overall score) between groups (all P>0.05). The frequency of adverse events was similar and no serious adverse events were
reported during the study.
Conclusion: Tryptophan was unlikely to be effective for mental symptoms, but could alleviate sleep disorders in short term among
detoxiﬁed individuals with new-type drug dependence. Future large-scale trials are required to conﬁrm ﬁndings from this study.
Abbreviations: 5-HT = serotonin, AIS = Athens Insomnia Scale, SCL-90 = Symptom Checklist-90.
Keywords: mental symptom, new-type drug dependence, sleep disorders, tryptophan[3,4]1. Introduction
Distinguished from traditional drugs (such as opium and heroin),
new-type drugs are a category of emerging synthetic drugs, such
as methamphetamine, ecstasy, and ketamine.[1,2] In western
countries, new-type drugs are often referred as “club drugs,”
because of being popular with adolescents and young adults inEditor: Michele Fornaro.
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Recently, the use of new-type drugs has been increasing,[5,6] and
new-type drug dependence has become a major public health
problem in many parts of the world.[7,8] In China, amphetamine-
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Wang et al. Medicine (2016) 95:28 MedicineLong-term use of new-type drugs can lead to psychological
disorders, including anxiety, depression, sleeping disorders, and
social problems.[10,11] Previous studies indicated that new-type
drugs are associated with psychological disorders through the
reward system, such as serotonergic system, dopaminergic
system and g-aminobutyric acid system.[12,13] New-type drugs
act on presynaptic neurons, and promote the release of
more serotonin (5-HT) and dopamine. Repeated use of new-
type drugs will lead to adaptation in 5-HT and dopamine
function. Consequently, neurotransmitters such as dopamine
and 5-HT will be depleted or much less than needed.
Despite knowing this mechanism, however, no medications
have been proven to be effective for the treatment of new-type
drug dependence.[14,15]
Tryptophan is the precursor of 5-HT, and a high level of
tryptophan could increase 5-HT synthesis,[16] which may
modulate mood and sleeping disorders.[17–20] Findings from a
literature review suggested that tryptophan could improve mood
in vulnerable subjects, and improves sleep in adults with sleep
disturbances, by increasing brain 5-HT.[21]Moreover, it may also
be efﬁcacious for syndromes associated with nicotine and heroin
withdrawal.[22,23]
We speculated that the increased 5-HT level with the
supplement of tryptophan would attenuate mood and sleeping
disorders. This study aimed to test the hypothesis that tryptophan
would attenuate mental symptoms and sleeping disorders among
individuals with new-type drug dependence.2. Methods
2.1. Subjects
Eighty participants were recruited successively from a compul-
sory detoxiﬁcation center in Wuhan, China from April 2012 to
November 2012. The center provides compulsory addiction
treatment to patients with drug dependency, where they usually
have to stay for 2 years after being held with a positive urinary
sample. Investigators provided study information to patients,
and invited them to participate in the study. The participation
in this study was voluntary, and patients were allowed to
stop participation at any time during the study period.
Study participants were recruited according to the following
inclusion criteria: new-type drug dependence veriﬁed by
the Structured Clinical Interview for the DSM-IV-TR; being
treated in the detoxiﬁcation center for about a week; aged 18 or
above; suffering from mental or sleeping disorders veriﬁed by
Symptom Check-List-90 (SCL-90) and Athens Insomnia Scale
(AIS); and willing and able to comply with the study, and
with written informed consent. Patients were excluded
according to the following exclusion criteria: substance
dependence other than new-type drugs; a current neurological
disease (e.g., organic brain disease) or schizophrenia assessed
by Structured Clinical Interview for the DSM-IV-TR; the
score of AIS<4[24]; pregnant women; a history of dysfunction
of liver, heart, or kidney; serious endocrine and circulatory
disorders; currently taking other psychiatric medications;
unable to comply with the study procedure; without giving
informed consent; and other circumstances that would affect
participant’s safety.
The study was approved by the institutional review board at
the School of Public Health, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China. All study
participants signed the written informed consent. The study was2prospectively registered online and the Clinical trial registration
number was ChiCTR-TRC-12002492.2.2. Design
This was a randomized, double-blind, placebo-controlled trial.
Eighty eligible participants were randomly assigned to a
tryptophan (1000mg/d, n=40) group or a placebo (glucose
1000mg/d, n=40) group. The intervention (and its dose) was
based on ﬁndings from previous studies.[25,26] A simple
randomization schedule was used, and allocation was performed
according to a list of computer-generated random numbers by an
independent researcher. The medication was provided by Tianjin
Tian’an Pharmaceuticals Co., Ltd., Tianjin, P. R. China. The
tryptophan and placebo bottles were numbered 3 and 5,
respectively, and dispensed by nurses in the detoxiﬁcation center.
Both study participants and nurses were blinded to the treatment
provided. Participants took medication orally twice a day for 14
days in total, under a nurse’s direct supervision.
The sample size calculation was based on the score of AIS.
Previous research indicated a standard deviation of 2.2, and a
mean change of AIS scores of 3.9 in the treatment group and 1.7
in the control group, respectively. With a 5% 2-sided alpha and
80% power, a minimum of 74 were required. Considering the
possible follow-up loss, 80 subjects were enrolled.2.3. Measures
The demographic characteristics and new-type drug use variables
at baseline were measured using self-devised questionnaire.
Sleeping status and mental symptoms of participants were
assessed using AIS[27] and SCL-90,[28] respectively.
The AIS is a self-reported instrument consisting of 8 items. The
ﬁrst 4 items are sleep quantitative variables (i.e., sleep induction,
night awakenings, early morning awakening, and total sleep
time), the ﬁfth item concerns sleep quality, and the remaining
ones relate to the next-day performance of insomnia. Each item
can be rated from 0 (not at all) to 3 (very serious), so that the total
score ranges from 0 to 24. Patients with insomnia usually have an
AIS score at least 4. The Cronbach alpha of the scale was 0.81 in
Chinese.[29] Despite AIS was initially used to evaluate subjects’
sleep status within the last month, we used it to assess weekly
sleep status, according to a previous study of patients with heroin
dependence.[23]
The SCL-90 scale consists of 90 items and the following 9
dimensions: somatization, obsessive-compulsive disorder, inter-
personal sensitivity, depression, anxiety, hostility, phobic anxi-
ety, paranoid ideation, and psychoticism. It is a self-
administrated scale based on a 5-point rating method, ranging
from 0 (not at all) to 4 (extremely). The Cronbach alpha of the
scale was above 0.65, with good reliability and validity for
substance abusers.[30]
The mental symptoms and sleeping status were assessed at
baseline, 1 week and 2weeks after randomization. The adherence
was measured daily by asking participants if they wanted to
continue, and they could drop out of the trial whenever they
wanted. Adverse events were assessed daily by asking partic-
ipants open-ended questions such as “Have you had any
problems or side effects (such as nausea, headache or any other
problem)”? Nurses recorded both adherence and adverse events.
For serious adverse events, nurses could inform a physician for
treatment if necessary. Physicians were not blinded with the
treatment allocation in order to cope with possible emergencies.
Wang et al. Medicine (2016) 95:28 www.md-journal.com2.4. Data analysis
Data were analyzed using SPSS for Windows (version 12.0).
Continuously distributed variables were analyzed using mean
(standard deviation or standard error), and categorical variables
using frequencies and percentages. Baseline characteristics
between groups were compared using Wilcoxon rank sum test
for continuous data, and x2 or Fisher exact test for categorical
data. Results were analyzed according to intent-to-treat principle.
Differences in changes of AIS and SCL-90 scores from baseline to
week 2 between groups were assessed using t test. When outcome
data at week 2 were not available due to loss to follow-up, data at
week 1 or baseline were used in the analysis. The adherence and
adverse events were analyzed using x2 test. All statistical tests
were 2-tailed, with a statistical signiﬁcance level of <0.05.3. Results
3.1. Baseline characteristics
A total of 323 individuals were assessed for eligibility and 243
were excluded, of which 230 did not meet the inclusion criteria
and 13 refused to participate. We included 80 patients in the
study, and randomly allocated them to the treatment (n=40) and
the control group (n=40; Fig. 1).
There were no signiﬁcant differences in participant character-
istics at baseline between the 2 groups (Table 1). In addition, there
were no signiﬁcant differences inAIS andSCL-90 scores at baseline
between the groups (Table 2). The majority of participants was
male (67.5%), unmarried (47.5%), with a mean age of 33.2 (±9.4323 Individuals screened
80 Randomized
Baseline
40 Received tryptophan
Week 1
40 Completed
16 Lost to follow up
15 Refused to continue
1 For uncomfortable feeling
Week 2
24 Completed the study 
40 Included in efficacy analysis
Figure 1. Study part
3years), and low education level. Magu (69.0%) was the most
frequently reported new-type drug used, followed by mixed new-
type drug (16.3%) and ketamine (11.2%). New-type drugs were
mainly smoked, and the mean lifetime years of drug use was 5.2
years (±4.5 years).Moreover, 90.0%of participants were tobacco
smokers, and 45.0% alcohol drinkers.3.2. Adherence
Forty-ﬁve participants (56.3%) in total completed the 2-week
treatment, 24 in the tryptophan group and 21 in the placebo
group (x2=0.46, P=0.50). There were no signiﬁcant differences
in baseline characteristics between the treatment and control
group for the 45 participants who completed the treatment
(Table 3). Reasons given for quitting the study were similar
between the groups, as the following: side effects (tryptophan
15%, 6/40; placebo 17.5%, 7/40, x2=0.09, P=0.76), lack of
efﬁcacy (tryptophan 12.5%, 5/40; placebo 17.5%, 7/40, x2=
0.39, P=0.53), and being sent to jail (tryptophan 12.5%, 5/40;
placebo 12.5%, 5/40, x2=0, P=1).3.3. Treatment efﬁcacy
The AIS score was reduced on average by 3.53 in the tryptophan
group and by 1.55 in the control group. The difference between
the groups was statistically signiﬁcant (mean difference 1.975;
P=0.017). However, there were no statistically signiﬁcant
differences in SCL-90 scores in term of individual items and
the overall score (Table 4).243 Excluded
230 Did not meet inclusion criteria
13 Declined to participate
40 Included in efficacy analysis
Baseline
40 Received placebo
19 Lost to follow up
17 Refused to continue
2 For uncomfortable feeling
Week 1
40 Completed
Week 2
21 Completed the study
icipant ﬂow chart.
Table 1
The main characteristics of participants at baseline.
Tryptophan N (%) (n=40) Placebo N (%) (n=40) Total N (%) (n=80) P
∗
Demographics
Age, y, mean (SD) 31.4 (8.2) 35.0 (10.3) 33.2 (9.4) 0.11
Gender (male) 29 (72.5) 26 (65.0) 55 (67.5) 0.47#
Marital status 0.35
Married 9 (22.5) 13 (32.5) 22 (27.5)
Unmarried 21 (52.5) 17 (42.5) 38 (47.5)
Divorced 8 (20.0) 8 (20.0) 16 (20.0)
Widowed 0 2 (5.0) 2 (2.5)
Others 2 (5.0) 0 2 (2.5)
Education 0.89
Primary school or lower 5 (12.5) 4 (10.0) 9 (11.3)
Middle school 17 (42.5) 18 (45.0) 35 (43.7)
Senior middle school 13 (32.5) 15 (37.5) 28 (35.0)
College or above 5 (12.5) 3 (7.5) 8 (10.0)
Employment 1.00
Student 0 1 (2.5) 1 (1.0)
Employed 22 (55.0) 22 (55.0) 44 (55.0)
Unemployed 18 (45.0) 17 (42.5) 35 (43.7)
Family relationship 0.40#
Good 18 (45.0) 14 (35.0) 32 (40.0)
General 14 (35.0) 20 (50.0) 34 (42.5)
Not good 8 (20.0) 6 (15.0) 14 (17.5)
New-type drug use
Lifetime years of new-type drug use, mean (SD) 4.8 (4.2) 5.6 (4.8) 5.2 (4.5) 0.39
Type of new-type drug use 0.09
Magu 23 (57.5) 32 (80.0) 55 (69.0)
Mixed new type 7 (17.5) 6 (15.0) 13 (16.3)
Ketamine 7 (17.5) 2 (5.0) 9 (11.2)
Methamphetamine 2 (5.0) 0 2 (2.5)
Ecstasy 1 (2.5) 0 1 (1.0)
Route of new-type drug administration 0.78
Smoked 26 (65.0) 28 (70.0) 54 (67.5)
Snorted 9 (22.5) 5 (12.5) 14 (17.5)
Ingested orally 2 (5.0) 4 (10.0) 6 (7.5)
Injection 1 (2.5) 1 (2.5) 2 (2.5)
Others 2 (5.0) 2 (5.0) 4 (5.0)
Cigarette smoking 36 (90.0) 36 (90.0) 72 (90.0) 1.00#
Alcohol drinking 16 (40.0) 20 (50.0) 36 (45.0) 0.37#
SD= standard deviation.
∗
Group means were compared using Wilcoxon rank sum test, and categorical variables were compared using x2 test (#) or Fisher exact test.
Table 2
Characteristics of SCL-90 and AIS between groups preintervention.
Tryptophan (n=40) Placebo (n=40) Total
Mean SD Mean SD Mean SD P
∗
Somatization 2.0 0.9 1.9 0.8 2.0 0.8 0.71
Obsessive–compulsive disorder 2.0 0.9 2.1 0.8 2.1 0.8 0.6
Interpersonal sensitivity 1.8 1.0 1.9 0.7 1.9 0.8 0.22
Depression 2.1 0.9 2.1 0.8 2.1 0.9 0.9
Anxiety 1.9 0.9 1.9 0.8 1.9 0.9 0.42
Hostility 1.9 1 1.9 0.9 1.9 1.0 0.68
Phobic anxiety 1.5 0.8 1.5 0.6 1.5 0.7 0.91
Paranoid ideation 1.9 0.9 1.8 0.8 1.8 0.8 0.46
Psychoticism 1.8 0.9 1.7 0.6 1.8 0.8 0.9
Total 1.9 0.8 1.9 0.7 1.9 0.8 0.91
AIS score 10.3 4.9 9.4 4.1 9.8 4.5 0.47
AIS=Athens Insomnia Scale; SD= standard deviation.
∗
Group means were compared using Wilcoxon rank sum test.
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Table 4
Changes in AIS and SCL-90 scores from baseline to week 2 by treatment groups.
Changes from baseline to week 2 Difference between groups
Placebo mean (SE) Tryptophan mean (SE) Mean (SE) P
∗
AIS score 1.550 (0.408) 3.525 (0.695) 1.975 (0.806) 0.02
SCL-90 score
Somatization 0.363 (0.083) 0.350 (0.101) 0.013 (0.131) 0.92
Obsessive–compulsive 0.453 (0.101) 0.435 (0.110) 0.018 (0.150) 0.91
Interpersonal sensitivity 0.417 (0.088) 0.474 (0.134) 0.057 (0.160) 0.72
Depression 0.442 (0.091) 0.548 (0.118) 0.106 (0.150) 0.48
Anxiety 0.413 (0.074) 0.365 (0.120) 0.048 (0.141) 0.74
Hostility 0.433 (0.112) 0.467 (0.138) 0.034 (0.178) 0.85
Phobic anxiety 0.207 (0.070) 0.332 (0.120) 0.125 (0.139) 0.37
Paranoid ideation 0.329 (0.105) 0.492 (0.110) 0.163 (0.152) 0.29
Psychoticism 0.290 (0.078) 0.393 (0.120) 0.103 (0.143) 0.48
Other 0.146 (0.090) 0.471 (0.117) 0.326 (0.148) 0.03
AIS=Athens Insomnia Scale; SCL-90=Symptom Check-List-90; SE= standard error.
∗
Differences in mean change from baseline to week 2 between the 2 groups were compared using Student t test.
Table 3
Characteristics of the remaining 45 participants.
Tryptophan N (%) (n=24) Placebo N (%) (n=21) Total N (%) (n=45) P
∗
Demographics
Age, mean (SD), y 35.8 (8.2) 37.1 (11.4) 36.4 (9.8) 0.65
Gender (male) 19 (79.2) 15 (71.4) 34 (75.6) 0.55#
Marital status 0.75
Married 6 (25.0) 8 (38.1) 14 (31.1)
Unmarried 12 (50.0) 10 (47.6) 22 (48.9)
Divorced 5 (20.8) 3 (14.3) 8 (17.8)
Others 1 (4.2) 0 1 (2.2)
Education 0.58
Primary school or lower 4 (16.7) 2 (9.5) 6 (13.3)
Middle school 8 (33.3) 11 (52.4) 19 (42.3)
Senior middle school 8 (33.3) 6 (28.6) 14 (31.1)
College or above 4 (16.7) 2 (9.5) 6 (13.3)
Employment 0.28
Student 0 1 (2.5) 1 (2.2)
Employed 16 (66.7) 10 (55.0) 26 (57.8)
Unemployed 8 (33.3) 10 (42.5) 18 (40.0)
Family relationship 0.69
Good 14 (58.3) 10 (47.6) 24 (53.3)
General 7 (29.2) 9 (42.9) 16 (35.6)
Not good 3 (12.5) 2 (9.5) 5 (11.1)
New-type drug use
Lifetime years of new-type drug use, mean (SD) 7.6 (3.6) 8.5 (5.1) 8.0 (4.3) 0.50
Type of new-type drug use 1.00
Magu 15 (62.5) 15 (71.4) 30 (66.7)
Mixed new type 5 (20.8) 5 (23.8) 10 (22.2)
Ketamine 2 (8.3) 1 (4.8) 3 (6.7)
Methamphetamine 1 (4.2) 0 1 (2.2)
Ecstasy 1 (4.2) 0 1 (2.2)
Route of new-type drug administration 0.74
Smoked 17 (70.8) 14 (66.7) 31 (68.9)
Snorted 5 (20.8) 3 (14.3) 8 (17.8)
Ingested orally 1 (4.2) 3 (14.3) 4 (8.9)
Others 1 (4.2) 1 (4.7) 2 (4.4)
Cigarette smoking 22 (91.7) 19 (90.5) 41 (91.1) 1.00
Alcohol drinking 11 (40.0) 13 (50.0) 24 (53.3) 0.28#
SD= standard deviation.
∗
Group means were compared using Wilcoxon rank sum test, and categorical variables were compared using x2 test (#) or Fisher exact test.
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Table 5
Changes in AIS score from baseline to week 2: results of multiple variable linear regression analysis.
Variables Coefﬁcient: b (SE) P
Tryptophan (1) or placebo (0) 2.268 (0.829) 0.008
Age (year) 0.057 (0.051) 0.27
Male (1) versus female (0) 0.415 (0.966) 0.67
Education middle school (1) versus other (0) 1.259 (0.897) 0.17
Unemployed (1) versus other (0) 0.657 (0.860) 0.45
Cigarette smoking (1) versus other (0) 1.582 (1.481) 0.29
Alcohol drinking (1) versus other (0) 0.781 (0.830) 0.35
Years of drug use 0.129 (0.096) 0.18
b<1 indicates that a variable is associated with a lower AIS score.
AIS=Athens Insomnia Scale; SE= standard error.
Wang et al. Medicine (2016) 95:28 MedicineWe conducted a linear regression analysis to evaluate the
efﬁcacy of tryptophan on sleep disorders (AIS scores) after
adjusting for multiple baseline variables, including age, gender,
married or not, education level, unemployment, smoking,
drinking, and years of drug use. The results of the multiple
variable regression analysis found that the treatment with
tryptophan was the only variable that was statistically signiﬁ-
cantly associated with changes in AIS scores, and other baseline
variables were not signiﬁcantly associated with changes in AIS
scores (Table 5).3.4. Safety
Adverse events were reported by 13 of the 80 participants
(16.3%), 6 in the tryptophan group (15%) and 7 in the placebo
group (17.5%). The difference in frequency of adverse events
between the 2 groups was not statistically signiﬁcant (x2=0.09,
P=0.76). The common adverse events included: nausea (7 in the
treatment and 6 in the placebo group, P=0.76), headache (4 in
the treatment and 3 in the placebo group, P=0.69), and chest
pain (6 in the treatment and 4 in the placebo group, P=0.50). All
these adverse events were mild and no serious events reported
during the study.4. Discussion
To our knowledge, the current study was the ﬁrst to empirically
evaluate the efﬁcacy of tryptophan on sleeping disorders and
mental symptoms in patients with new-type drug dependence in
China. In our study, the AIS score was reduced by 5.5 in the
tryptophan group, and it was only 1.6 in the placebo group, and
the difference between the groups was statistically signiﬁcant.
Therefore, tryptophan may mitigate sleeping disorders of
detoxiﬁed individuals with new-type drug dependence. This
ﬁnding was similar to previous studies in heroin addicts[23] and
adults with sleep disturbances.[21] It has great signiﬁcance for
patients with new-type drug dependence, as sleeping disorders
are usual withdrawal symptoms for individuals with new-type
drug dependence.[31,32]
Findings from this study indicated that treatment with
tryptophan for 2 weeks had no effect on mental symptoms of
detoxiﬁed individuals with new-type drug dependence, in terms
of all dimensions of the SCL-90 scale, which was similar to
previous studies of medications for methamphetamine depen-
dence.[33,34] Furthermore, it revealed that mental symptoms may
not change simultaneously with changes in sleep disorders. It is
possible that mental symptoms and sleep disorders involve6different neurobiological mechanisms or additional path-
ways.[35,36]
Tryptophan appeared to be safe and well tolerated. There were
no serious adverse events reported. However, the adherence in
the tryptophan and placebo group was similarly low, which was
consistent with other clinical trials of methamphetamine
users.[37,38] Adherence was usually an issue in follow-up studies,
and our study was no exception, even though participants of the
study were from a compulsory detoxiﬁcation center. Low
adherence may be associated with suspicious attitudes, which
was a typical psychiatric symptom among individuals with new-
type drug dependence.[39]
In terms of the participant characteristics at baseline, most
new-type drug users were male and relatively young, which was
similar to the 2010 drug users reported by the State Food and
Drug Administration and a Chinese study.[9] Magu was the most
frequently used new-type drug, as an emerging drug in China,
and its ingredients include methamphetamine and caffeine. This
was different from other studies of methamphetamine,[40,41]
which may be due to different geographic areas or reﬂect a real
change over time.
The current study had some limitations. Firstly, patients in the
current study were treated for only 2 weeks. A previous study
showed that amphetamine users experienced a long period of
insomnia after ceasing amphetamine use for 3 days.[42] Another
study revealed that the sleep time of amphetamine users was
shorter than controls after using drugs.[43] Moreover, the
treatment adherence in medication trials was usually low.
Considering all the above reasons, we treated patients in the
current study for 2 weeks. Secondly, other confounding factors,
which could affect sleep in such subjects may still not be included
in our study, though a multiple variable regression analysis found
that the observed treatment effect of tryptophan on sleep
disorders was not due to imbalanced distribution of baseline
characteristics between the groups (Table 5). Thirdly, our study
just focuses on the effect of tryptophan on the sleeping disorder
and mental symptom in patients with new-type drug dependence,
not the treatment of addiction to these substances, which needs to
be conﬁrmed in further studies. Finally, the current study was
very small, with a total of 80 participants. Thus, a larger,
multisite, and longer-term trial needs to be conducted to conﬁrm
the present results.
In summary, the current study indicated that tryptophan was
unlikely effective in reducing mental symptoms, but might be
effective for alleviating sleep disorders in individuals with new-
type drug dependence in short term, although this needs to be
conﬁrmed in a future deﬁnitive trial. This might provide a new
[20] van Dalfsen JH, Markus CR. Interaction between 5-HTTLPR genotype
Wang et al. Medicine (2016) 95:28 www.md-journal.cominsight to the treatment of sleeping disorders of patients with
new-type drug dependence. Further well-designed large-scale
randomized controlled trials are required to conﬁrm the results.Acknowledgments
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